University of Oxford scientists on Tuesday announced that a trial of dexamethasone, a common steroid used to treat inflammation, showed a major breakthrough in the treatment of COVID-19. Severely ill patients who received the drug were more likely to survive than those who didn’t.

Although the study’s results were discussed in a news release Tuesday, the findings have not yet been peer-reviewed or officially published in a journal.

In the trial, 2,104 COVID-19-positive patients received 6 milligrams of dexamethasone once every day for 10 days. The study participants’ health outcomes were compared with 4,321 patients who received the usual care, but no dexamethasone.

Read more…